Drugs.com - Clinical Trials

BlueRock Therapeutics Announces Publication in Nature of 18-Month Data from Phase 1 Clinical Trial for Bemdaneprocel, an Investigational Cell Therapy for Parkinson’s Disease

Cambridge MA, USA, April 16, 2025 – BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, today announced the publication of the 18-month data from its Phase 1 exPDite clinical trial for...

Apr 22, 2025 - 00:22
 0
BlueRock Therapeutics Announces Publication in Nature of 18-Month Data from Phase 1 Clinical Trial for Bemdaneprocel, an Investigational Cell Therapy for Parkinson’s Disease
Cambridge MA, USA, April 16, 2025 – BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned subsidiary of Bayer AG, today announced the publication of the 18-month data from its Phase 1 exPDite clinical trial for...
Read More

Tags:

Previous Article

China and Egypt Kick Off First Joint Aerial Drills

Next Article

Mountain Dew Mango Rush Lands at Little Caesars in Flavor-Packed Collaboration

Related Posts

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen Initiates Phase 3 Study of Felzartamab for the T...

Mar 11, 2025  0

NIH Researchers Discover Novel Class of Anti-Malaria Antibodies

NIH Researchers Discover Novel Class of Anti-Malaria An...

Feb 9, 2025  0

Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First Prescription Digital Therapeutic for the Preventive Treatment of Episodic Migraine in the United States

Click Therapeutics Announces FDA Marketing Authorizatio...

Apr 22, 2025  0